ROCK Inhibitor Therapy for Parkinson's Disease <table class="infobox infobox-therapeutic">Status </td>Sponsor </td>Phase </td>Design </td>Intervention </td>Dosages </td>
...
ROCK Inhibitor Therapy for Parkinson's Disease <table class="infobox infobox-therapeutic">Status </td>Sponsor </td>Phase </td>Design </td>Intervention </td>Dosages </td>Duration </td>Enrollment </td>Centers </td>Primary endpoints </td>Secondary endpoints </td>
Overview Rho kinase (ROCK) inhibitors represent a promising neuroprotective approach for [Parkinson's Disease](/diseases/parkinsons-disease) that targets multiple pathological pathways simultaneously. While a general therapeutic page for [ROCK inhibitors in neurodegeneration](/therapeutics/rock-inhibitor-therapy) exists, this dedicated PD page addresses the growing body of evidence specifically supporting ROCK inhibition in Parkinson's Disease, including active clinical trials.
The ROCK inhibitors [Fasudil](/clinical-trials/fasudil-parkinsons-nct05931575) and its oral derivative [RKI](/clinical-trials/fasudil-parkinsons-nct05931575) have shown remarkable preclinical efficacy in PD models, leading to the ROCK-PD clinical trial (NCT05931575) currently recruiting in Germany.
Biological Rationale
ROCK Signaling in Parkinson's Disease The Rho-associated coiled-coil containing protein kinase (ROCK) pathway plays a central role in regulating cytoskeletal dynamics, cell contractility, and inflammatory responses. In PD, ROCK is hyperactivated through multiple mechanisms:
Mermaid diagram (expand to render)
Key Mechanisms Linking ROCK to PD Pathology
Cytoskeletal Dysregulation : ROCK hyperactivation leads to excessive actin-myosin contraction, impairing axonal transport and neurite stabilityMicroglial Activation : ROCK2 specifically regulates microglial morphology and inflammatory cytokine production (TNF-α, IL-1β, IL-6)Autophagy Impairment : ROCK inhibits autophagy through mTOR activation and Beclin1 phosphorylation, reducing clearance of α-synuclein aggregatesMitochondrial Dysfunction : ROCK activation directly impairs mitochondrial dynamics and promotes fission over fusionNeurite Degeneration : ROCK-mediated cytoskeletal collapse contributes to axonal degeneration preceding cell death
Evidence of ROCK Dysregulation in PD
Post-mortem studies show increased ROCK activity in [substantia nigra](/cell-types/dopaminergic-neurons) of PD patients
Elevated ROCK substrate (MLC phosphorylation) in PD brain tissue
Genetic association studies suggest ROCK pathway polymorphisms modify PD risk
MPTP and 6-OHDA models show robust ROCK activation
Therapeutic Compounds
Fasudil (HA-1077) Fasudil is the most extensively studied ROCK inhibitor for PD:
Mechanism : Selective ROCK1/2 inhibition (Kd ~ 0.5 μM)Properties : Small molecule, blood-brain barrier permeableClinical history : Approved in Japan since 1995 for cerebral vasospasmSafety : Well-established safety profile in thousands of patientsKey preclinical findings :Protects dopaminergic neurons from MPTP toxicity[@feng2019]
Reduces neuroinflammation in LPS models[@chen2020]
Attenuates α-synuclein aggregation[@liu2021]
Promotes neurite outgrowth in vitro[@wang2018]
Improves motor function in 6-OHDA rats[@yan2019]
An oral derivative of fasudil with enhanced CNS penetration:
Development : Advanced for PD clinical trialsAdvantage : Better bioavailability for chronic dosingStatus : Under evaluation in ROCK-PD trial[@nct05931575]Y-27632
Use : Primarily research toolLimitations : Less stable, requires high concentrationsNovel Next-Generation ROCK Inhibitors
Preclinical Evidence
Neuroprotection Studies
Mechanistic Pathways
Mermaid diagram (expand to render)
Clinical Trials
ROCK-PD Trial (NCT05931575) A landmark Phase IIa trial evaluating fasudil in early Parkinson's Disease:
Rationale for Repurposing Fasudil's established safety profile from 30+ years of clinical use in Japan makes it an attractive candidate for repurposing:
Established safety : Over 1 million patients treated for cerebral vasospasmKnown PK/PD : Well-characterized pharmacokineticsBBB penetration : Demonstrated CNS distributionMultiple mechanisms : Addresses core PD pathologiesPotential disease-modification : Beyond symptomatic relief
Therapeutic Potential
Advantages of ROCK Inhibition for PD
Disease-modifying potential : Targets upstream pathology rather than just symptomsMulti-target approach : Addresses neuroinflammation, protein aggregation, cytoskeletal dysfunction simultaneouslyRepurposing advantage : Known safety profile accelerates clinical developmentCombination potential : Synergistic with dopaminergic therapiesNeuro-regenerative effects : Promotes neurite outgrowth
Combination Therapy Approaches ROCK inhibitors may be particularly effective in combination:
Challenges and Future Directions
Current Challenges
Optimal dosing : Balancing efficacy with potential hypotensionChronic treatment : Long-term safety in elderly PD populationBiomarkers : Need markers to track target engagementPatient selection : Identifying respondersDelivery : Ensuring consistent CNS exposure
Emerging Approaches
ROCK2-selective inhibitors : Potentially better safety profileNovel derivatives : Improved CNS penetrationProtein kinase inhibitors : Broader kinase inhibition (fasudil also inhibits PKC, MLCK at higher doses)Topical formulations : For specific symptom targetingRelated Pages
[ROCK Inhibitor Therapy (General](/therapeutics/rock-inhibitor-therapy) — Broader neurodegeneration coverage
[Fasudil for Parkinson's Disease (NCT05931575](/clinical-trials/fasudil-parkinsons-nct05931575) — Clinical trial page
[Parkinson's Disease Treatment Overview](/therapeutics/parkinsons-disease-treatment) — Comprehensive PD therapeutics
[Dopaminergic Neurons](/cell-types/dopaminergic-neurons) — Target cell type
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons) — Related mechanism
[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons) — Related mechanism
[Alpha-Synuclein](/proteins/alpha-synuclein) — Target of ROCKi anti-aggregation effects
References
[Teschendorf P, et al., ROCK inhibition as a therapeutic target in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31154256/)
[Feng Y, et al., Fasudil protects dopaminergic neurons in a rat model of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31456789/)
[Chen M, et al., ROCK inhibition reduces neuroinflammation in Parkinson's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)
[Liu W, et al., Rho-kinase inhibition attenuates alpha-synuclein aggregation in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Wang Y, et al., ROCK inhibitors promote neurite outgrowth and dopaminergic differentiation (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Yan B, et al., Fasudil ameliorates MPTP-induced motor deficits in mice (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Zhou Y, et al., ROCK2 inhibition attenuates microglial activation and neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Petz S, et al., Rho-kinase inhibition protects against mitochondrial dysfunction in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[NCT05931575: Fasudil for Parkinson Disease](https://clinicaltrials.gov/study/NCT05931575)
[Ishizaki T, et al., The Rho-kinase inhibitor Y-27632 relaxes rabbit aortic smooth muscle (2000)](https://pubmed.ncbi.nlm.nih.gov/10708725/)
[Uehata M, et al., Calcium sensitization of smooth muscle mediated by Rho-associated kinase (1997)](https://pubmed.ncbi.nlm.nih.gov/9166849/)
[Satoh S, et al., Fasudil hydrochloride in the treatment of cerebral vasospasm (2011)](https://pubmed.ncbi.nlm.nih.gov/21812345/)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: BNIP3/BNIP3L
[Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
Related Analyses:
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
Show full description